Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods for prediction and prognosis of cancer, and monitoring cancer therapy

A therapeutic and prognostic technology, applied in the field of biomarkers to monitor the effect of cancer treatment, can solve problems such as unreported correlations

Inactive Publication Date: 2009-08-12
BAYER HEALTHCARE LLC
View PDF6 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although total VEGF-A has been tested in humans as a prognostic indicator of disease outcome, until the present invention no correlation between VEGF-165 levels prior to chemotherapy and treatment outcomes in patients had been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for prediction and prognosis of cancer, and monitoring cancer therapy
  • Methods for prediction and prognosis of cancer, and monitoring cancer therapy
  • Methods for prediction and prognosis of cancer, and monitoring cancer therapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0088] Example 1. Solid Phase Sandwich Microtiter ELISA of Human Serum and Plasma Sample Preparations

[0089] [083] Samples suitable for VEGF-165 ELISA analysis include human plasma treated with sodium heparin, citrate, or EDTA, as well as human serum. Special care must be taken in the preparation and assay of human serum and plasma due to possible interfering factors. Any flocculants should be removed from the samples by microcentrifugation prior to dilution. Serum or plasma samples for testing should have an initial concentration of approximately 12-13% (sample diluted 1:8 with sample diluent). For example, 40 μl of sample can be diluted into 280 μl of sample diluent and 100 μl added to each well of a microtiter plate.

[0090] Steps

[0091] [084] The following ELISA protocol was used in a sandwich ELISA (Oncogene Science, Cambridge, MA) to measure human VEGF-164 in human plasma or serum.

[0092] 1. Prepare the working solution (1X) for washing the plate (supplied as ...

Embodiment 2

[0110] Example 2. Plasma collected from patients with non-small cell lung cancer

[0111] [087] VEGF-165 levels were determined in duplicate samples using the Oncogene Science VEGF-165 ELISA (Oncogene Science, Cambridge, MA) according to the manufacturer's instructions. The mean of two measurements was determined for each patient. The mean VEGF-165 levels of the 31 patients in this study are reported in Table 1. Table 2 shows the radiometric mean tumor shrinkage in each patient group. The results indicated that the mean VEGF-165 level in patients who showed stable disease following treatment with response to Sorafenib was 67.9 pg / ml. Those patients who still showed progressive disease after Sorafenib treatment had a mean VEGF-165 level of 227.2 pg / ml. Those patients showing stable disease had a mean tumor shrinkage of 5.1%, while those with progressive disease had a mean tumor growth of 20.6%. These results can be shown in figure 1 and 2 middle.

[0112] Table 1: VEGF...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the efficacy of cancer treatment. Specifically, this invention relates to the use of VEGF-165 as a biomarker for multi-kinase inhibitors.

Description

field of invention [0001] [001] The present invention relates to biomarkers, uses of biomarkers for cancer prediction and prognosis, and uses of biomarkers for monitoring the effect of cancer treatments. In particular, the present invention relates to the use of VEGF-165 as a biomarker for multi-kinase inhibitors. Background of the invention [0002] [002] Vascular endothelial growth factor receptors (VEGFRs) and their ligands, vascular endothelial growth factors (VEGFs) play a key role in endothelial cell migration and proliferation. The VEGFR / VEGF system includes three receptors (VEGFR-1, VEGFR-2 and VEGFR-3) and four ligands (VEGF-A, B, C, D, and E and placental growth factor). In addition, VEGF-A consists of four subtypes, VEGF-121, VEGF-165, VEGF-185, and VEGF-204. It arises from another transcription of the VEGF-A gene. The receptor is a plasma transmembrane protein with an intracellular tyrosine kinase domain. As with other protein kinases, activation of VEGFRs is...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N5/06
CPCG01N33/57488G01N2800/52A61P35/00A61P35/02A61P43/00
Inventor J·J·埃尔廷W·P·卡尼P·J·哈默
Owner BAYER HEALTHCARE LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com